- Home
- MRNA
MRNA
Moderna Inc.
as 12-18-2024 1:40pm EST
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 16.5B | IPO Year: | 2018 |
| Target Price: | $79.50 | AVG Volume (30 days): | 7.6M |
| Analyst Decision: | Hold | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.80 - $170.47 | Next Earning Date: | 11-07-2024 |
| Revenue: | $5,081,000,000 | Revenue Growth: | -44.29% |
| Revenue Growth (this year): | -50.96% | Revenue Growth (next year): | -8.16% |
Stock Insider Trading Activity of Moderna Inc. (MRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Dec 6 '24 | Sell | $44.68 | 529 | $23,637.31 | 20,446 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Dec 2 '24 | Sell | $43.30 | 112 | $4,849.28 | 20,446 | |
| Hoge Stephen | MRNA | President | Dec 2 '24 | Sell | $43.30 | 314 | $13,595.29 | 1,443,904 | |
| Mock James M | MRNA | Chief Financial Officer | Nov 27 '24 | Sell | $42.79 | 1,420 | $60,760.52 | 11,066 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Nov 27 '24 | Sell | $42.79 | 1,418 | $60,674.94 | 20,446 | |
| Hoge Stephen | MRNA | President | Nov 27 '24 | Sell | $42.79 | 291 | $12,451.63 | 1,443,904 | |
| Hoge Stephen | MRNA | President | Nov 8 '24 | Sell | $46.10 | 277 | $12,771.00 | 1,443,904 | |
| Mock James M | MRNA | Chief Financial Officer | Oct 4 '24 | Sell | $60.12 | 715 | $42,985.80 | 11,066 |
Latest Moderna Inc. News
MRNA Breaking Stock News: Dive into MRNA Ticker-Specific Updates for Smart Investing
MT Newswires
7 hours ago
Argus Downgrades Moderna to Hold From Buy
Insider Monkey
7 hours ago
Hedge Funds Think That Moderna, Inc. (MRNA) Will Bounce Back Soon
Argus Research
8 hours ago
Analyst Report: Moderna Inc
Argus Research
9 hours ago
Market Digest: RY, AEE, ETR, EXC, K, RCL, BYON, MRNA
Motley Fool
10 hours ago
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Fortune
2 days ago
Moderna pauses its RSV vaccine trial for children after 5 infants are hospitalized in latest challenge of preventing disease
Investor's Business Daily
2 days ago
Palantir Falls Despite Nasdaq 100 News, MicroStrategy Rises; Super Micro Gets The Axe
Benzinga
2 days ago
What's Going On With Moderna Stock On Monday?
Compare MRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRNA Moderna Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.